Cristina Myers
Acute Care · Mount Vernon, ILNPI 1588115810
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 139 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Novartis at 26.1% of the total. Reporting peaked in 2023 at $732 and has fallen 78.6% since, to $157 in 2025.
Across 139 payments — averaging $16.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$583
- Amgen$375
- Merck$227
- AstraZeneca$190
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$141
- Abiomed$119
- plus $603 from 12 others
What the payments were for
- Food & beverage$2,22099%
- Education$181%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 44 | $583 |
| Amgen | 22 | $375 |
| Merck | 13 | $227 |
| AstraZeneca | 13 | $190 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $141 |
| Abiomed | 1 | $119 |
| Boehringer Ingelheim | 6 | $110 |
| E.r. Squibb & Sons, L.L.C. | 5 | $83 |
| Johnson & Johnson | 5 | $75 |
| Sanofi-aventis U.S. LLC | 4 | $70 |
| Pfizer | 4 | $59 |
| Bayer | 3 | $51 |
| Lexicon Pharmaceuticals, Inc. | 2 | $39 |
| Itamar Medical Inc | 2 | $37 |
| Medtronic | 2 | $29 |
| Abbott | 1 | $23 |
| Biotronik Inc. | 1 | $15 |
| Impulse Dynamics (USA) Inc. | 1 | $14 |
How this compares
$2,238 in reported general payments places this provider in the 85th percentile of 461 acute care providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 378 | $366,937 |
| EntrestoSacubitril/Valsartan | 94 | $93,794 |
| BrilintaTicagrelor | 99 | $76,061 |
| JardianceEmpagliflozin | 75 | $68,197 |
| XareltoRivaroxaban | 52 | $45,683 |
| MultaqDronedarone Hcl | 36 | $42,523 |
| Repatha SureclickEvolocumab | 30 | $29,453 |
| Praluent PenAlirocumab | 15 | $7,048 |
| FarxigaDapagliflozin Propanediol | 11 | $5,981 |
| Metoprolol Succinate | 449 | $5,209 |
| Ranolazine ErRanolazine | 56 | $4,250 |
| Midodrine Hcl | 48 | $3,818 |
| Flecainide Acetate | 58 | $2,202 |
| ClopidogrelClopidogrel Bisulfate | 155 | $2,087 |
| Atorvastatin Calcium | 202 | $1,819 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $59 | $366,937378 claims |
| NovartisEntresto | $583 | $93,79494 claims |
| AstraZenecaBrilinta, Farxiga | $190 | $82,042110 claims |
| Boehringer IngelheimJardiance | $110 | $68,19775 claims |
| Johnson & JohnsonXarelto | $75 | $45,68352 claims |
| Sanofi-aventis U.S. LLCMultaq | $70 | $42,52336 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 461 acute care providers in Illinois.
Other acute care in Mount Vernon
- Heather KnowlesMount Vernon$6K
- Tedra GrayChicago$78K
- Lynn HickmanArlington Heights$61K
- Gwen CassidyChicago$46K
- Laura CoyleOak Lawn$34K
- Erin DarguzasChicago$17K
- Amy BatesQuincy$14K
- Sarah MiyataChicago$11K
- Katie MeadorChicago$10K
- Dena PelletreauArlington Heights$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.